Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice With Intramuscular and Intranasal Adjuvants
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants.
CFO of Life Science Startup Axogen Shares How Firm Navigated Pandemic’s Health Care Disruptions
UF startup and UF Innovate | Sid Martin Biotech graduate Axogen, a life science company that is developing products for nerve repair, is ramping up hiring for scientists and engineers after navigating through the negative disruptions from the Covid-19 pandemic.
Breast Milk of Mothers Who Received COVID-19 Vaccine Contains Antibodies That Fight Illness
The breast milk of lactating mothers vaccinated against COVID-19 contains a significant supply of antibodies that may help protect nursing infants from the illness, according to new research from the University of Florida.
DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
UF Team Identifies Novel Targets for COVID-19 Antivirals
A multidisciplinary team of researchers at the University of Florida is making progress in their search for targets that could be used for developing treatments for infections with COVID-19. The team posted a paper to bioRxiv reporting the identification of 53 novel genes and pathways that could become druggable targets for antiviral therapies for COVID-19 plus a broad array of coronavirus types.
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
‘A Year of Change’: UF Reflects on COVID-19 Milestones
The University of Florida is reflecting back on the milestones made in the last year through the COVID-19 pandemic. From the initial lockdown in March 2020 to the rollout of vaccines in December, reflecting back on the year of change helps us see just how far we’ve come.
Patients With Severe COVID-19 Twice As Likely To Require Future Hospitalizations for Other Illnesses
People who have recovered from a bout of severe COVID-19 may still have a reason for concern about their health. A new University of Florida study has found that patients who had a severe case of the disease were more than twice as likely as patients who had mild or moderate COVID-19 to need hospitalization again for health problems caused by COVID-19 complications.
Mental Confusion, Disorientation May Be Early Warning Sign of Severe COVID-19
A new University of Florida study finds that patients with COVID-19 who displayed symptoms of disorientation and confusion were three times more likely to go on to develop severe COVID-19 than patients with the virus who did not experience neurological symptoms.
UF Health Researchers Join Global Effort To Track COVID-19 Pandemic and Others in Future
University of Florida Health researchers are joining an ambitious global effort led by The Rockefeller Foundation to better track the coronavirus and its variants and set up a network of collaborators to stop any nascent pandemic in the future.
